NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

citing the company’s impressive performance and potential synergies from its recent acquisition of Nevro Corp. This acquisition is anticipated to influence Globus Medical’s 2025 financial ...

Since November, shares of Globus Medical have displayed continued momentum ... net cash holdings of $270 million, although that Nevro operates with a modest net cash position, but the real ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

Globus Medical closed 2024 on a strong note with record financial performance, driven by sales growth, innovative product launches, and strategic acquisitions. The integration of Nevro Corporation ...

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

BTIG responded by raising its price target for Globus Medical shares to $94, maintaining a Buy rating, citing the company’s impressive performance and potential synergies from its recent acquisition ...

2025 Financial Guidance and Fourth-Quarter 2024 Earnings Conference Call and Webcast As previously announced on February 6, 2025, given the pending acquisition of Nevro by Globus Medical ...